Rocket Pharmaceuticals (NASDAQ:RCKT) announced its quarterly earnings, reporting an EPS of ($0.38), which beat the consensus estimate by $0.04. The stock saw a trading increase to $4.53, with a market capitalization of $490 million, despite some insider selling by the CEO and General Counsel. Analysts currently hold a consensus “Hold” rating for RCKT with an average price target of $14.36.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Rocket Pharmaceuticals (NASDAQ:RCKT) Posts Earnings Results, Beats Expectations By $0.04 EPS
Rocket Pharmaceuticals (NASDAQ:RCKT) announced its quarterly earnings, reporting an EPS of ($0.38), which beat the consensus estimate by $0.04. The stock saw a trading increase to $4.53, with a market capitalization of $490 million, despite some insider selling by the CEO and General Counsel. Analysts currently hold a consensus “Hold” rating for RCKT with an average price target of $14.36.